SynthesisScientific reports2026
Efficacy and safety of thalidomide in β-thalassaemia: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Review of Genetic and Epigenetic Regulation of Fetal Hemoglobin in β-Hemoglobinopathies: From Molecular Mechanisms to Clinical Applications.Mediterranean journal of hematology and infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalidomide has shown promise as an adjunct therapy for β-thalassaemia, yet its effectiveness and safety are uncertain. This systematic review and meta-analysis evaluate the efficacy and safety of thalidomide in β-thalassaemia; in both transfusion-dependent and non-transfusion-dependent patients. Scopus, PubMed and Cochrane databases were searched for studies assessing the efficacy and safety of thalidomide in β-thalassaemia. Primary outcomes included transfusion response and haemoglobin increases whereas adverse events and effects on serum ferritin and spleen size were secondary outcomes. Study quality, risk of bias and heterogeneity were assessed using standardized tools. Nineteen studies comprising 1731 patients met the eligibility criteria. Thalidomide halved the transfusion requirements in 76% patients with transfusion-dependent β-thalassaemia (response rate of 0.76 [95%CI: 0.67-0.83]) and achieved transfusion independence in 55% (good response rate of 0.55 [95%CI: 0.47-0.63]). In non-transfusion-dependent β-thalassaemia, > 1 g/dl and > 2 g/dL rise in haemoglobin were seen among 91% (response rate- 0.91 [95%CI: 0.81-0.96]) and 76% (good response rate- 0.76 [95%CI: 0.63-0.85]) of patients, respectively. The most frequent adverse effects were constipation (15% [95% CI: 13.7-17.2]) and somnolence (15% [95%CI: 13.6-17.1%]). Thalidomide appears to be effective and tolerable in β-thalassaemia. It reduced the transfusion requirement in transfusion-dependent β-thalassaemia patients and increased the haemoglobin levels in non-transfusion-dependent β-thalassaemia patients.Systematic review registration: CRD42024627095.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.